Provider review
Trimi Review: It Names the Trials, the Pharmacies and the Licence Number
Trimi is the best-disclosed company reviewed on this site, and the bar it clears is one nearly every competitor fails. It names the trials behind its claims — SURMOUNT-1 and SELECT, both in the New England Journal of Medicine. It then says the thing that makes naming them honest: "Figures are from peer-reviewed clinical trials of the active ingredients (semaglutide and tirzepatide), not a guarantee of individual results. Compounded medications are prepared per individual prescription and are not themselves FDA-approved as drugs." It names its regulatory category — state-licensed 503A — and its pharmacies, VialsRx with its Texas Board of Pharmacy number #35264, and GreenwichRx. It names its medical director. And it is the only company in this roster to mention a certificate of analysis at all. The catch is in three words: the certificate is "available on request", so nobody can read one before buying — and the $99 headline is an annual-plan rate, against $175 month to month.
Compounded only
Phase 3 trials
Named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens trytrimi.com. A link is not a recommendation to take anything.
Provenance
What Trimi actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded Semaglutide — $99 a month — and Trimi states the condition plainly: "Compounded semaglutide is $99 a month and tirzepatide $125 a month ON ANNUAL PLANS." The month-to-month figure verified on the sibling cost site is $175. "Same price at every dose — your price never changes as your dose is adjusted."
- Compounded Tirzepatide — $125 a month on an annual plan; $235 month to month per the sibling cost site's funnel walk. Dose does not change the price.
Evidence
Is there a human trial at all?
One row per product, graded on how far the published human evidence goes for the use it is sold for — not for the molecule in general. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Products with a human trial
Out of 2 reviewed here.
3
Registry records cited
Each read live from ClinicalTrials.gov, never from memory.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Trimi’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded SemaglutideSemaglutide · Compounded (503A)Claim matches the trials
“Up to 16% weight loss — Compounded Semaglutide $99/month. […] 20% lower risk of major heart events — SELECT trial (NEJM). Figures are from peer-reviewed clinical trials of the active ingredients (semaglutide and tirzepatide), not a guarantee of individual results. Compounded medications are prepared per individual prescription and are not themselves FDA-approved as drugs. Individual results vary.”
Phase 3 trials
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks — roughly 14.9% weight loss from baseline against 2.4% on placebo.
- NCT03574597 SELECT — Phase 3, completed, n=17,604. Semaglutide effects on heart disease and stroke in 17,604 people with overweight or obesity — the cardiovascular-outcomes trial Trimi cites by name.
This is the most complete claim any company in this review series makes, and every part of it holds. The figures are right — semaglutide's weight-loss programme reports in the mid-teens, and SELECT reported roughly a 20% reduction in major adverse cardiovascular events across 17,604 participants. The trials are NAMED rather than gestured at with "clinical studies show". And the qualifying sentence does the work that separates an honest citation from a borrowed one: "Figures are from peer-reviewed clinical trials of THE ACTIVE INGREDIENTS… not a guarantee of individual results. Compounded medications… are not themselves FDA-approved as drugs." That is precisely the distinction two companies in this wave hold open FDA warning letters for blurring, stated voluntarily. ⚠ The one thing left implicit: SELECT enrolled people with established cardiovascular disease, so a 20% risk reduction is not a figure a general weight-loss customer should expect to apply to themselves.1,2
Compounded TirzepatideTirzepatide · Compounded (503A)Claim matches the trials
“Up to 22% weight loss — Compounded Tirzepatide $125/month. […] SURMOUNT-1 trial (NEJM). Figures are from peer-reviewed clinical trials of the active ingredients (semaglutide and tirzepatide), not a guarantee of individual results. Compounded medications are prepared per individual prescription and are not themselves FDA-approved as drugs.”
Phase 3 trials
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tirzepatide over 72 weeks; roughly 20–22% mean weight reduction at the highest tolerated dose, with lifestyle intervention in every arm.
"Up to 22% weight loss" with SURMOUNT-1 named is accurate — the trial's highest-dose arm reported a mean reduction around that figure over 72 weeks, and "up to" is the correct qualifier for a top-of-range number. The same disclaimer covers it: the figures come from trials of the active ingredient, not of Trimi's compounded preparation, and the compounded product is not FDA-approved as a drug. Naming the trial means a reader can go and check the number, which is the whole point and which almost nobody here allows.3
Dispensing chain
Who actually fills your prescription
- VialsRx — Texas Board of Pharmacy #35264
- GreenwichRx
Read the full account
The best supply-chain disclosure in the roster, and the only one that publishes a licence number. Trimi states, under a heading reading "Named, licensed pharmacies": "Your medication is compounded by state-licensed 503A pharmacies, including VialsRx (Texas Board of Pharmacy #35264) and GreenwichRx, with a certificate of analysis available on request." Four separate things there are unusual: the regulatory category is stated (503A, twice on the page), the pharmacies are named, one carries a STATE BOARD LICENCE NUMBER a reader can verify independently, and a certificate of analysis is acknowledged to exist. It adds the preparation basis too — "Compounded semaglutide and tirzepatide are prepared per individual prescription by a state-licensed pharmacy and are not FDA-approved as drugs." ⛔ THE CERTIFICATE IS "AVAILABLE ON REQUEST", NOT PUBLISHED — so a prospective customer still cannot read one before deciding, which is why this review records no public certificate. Being the only company here to acknowledge one is nonetheless a real distinction. ⚠ The clinical side is named as fully: "licensed providers through Arora Health, a network spanning all 50 states and led by Medical Director Dr. Sean Arora, MD." ⚠ VialsRx is the third brand on this site to name it — Auren Rx and telos rx also do — and GreenwichRx appears as a pharmacy line in a fourth company's catalogue. A shared pharmacy layer is common in this category and is NOT grounds to treat any of these brands as duplicates. ⚠ What is still not disclosed is which of the two fills a given order.
Read on August 2026 from https://trytrimi.com
Quality
Third-party testing, and what is published
Yes
Describes a testing regime
A described programme, not a document.
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
Trimi is the only company in this roster to mention a certificate of analysis at all, and the exact wording matters: a COA is "available on request". So testing is acknowledged and a document is said to exist — hence `publishesTesting` true — while `coaPublic` is FALSE, because a certificate a prospective customer cannot read before buying is not a public one. That is a genuine distinction and it is worth stating in both directions: no other company here even claims a certificate exists, and Trimi still does not let you read it first. ⚠ What it does publish that nobody else does is a verifiable identifier: VialsRx's Texas Board of Pharmacy number, #35264, which a reader can check against the state board independently of anything Trimi says. Combined with the explicit "state-licensed 503A" category and the statement that products "are not themselves FDA-approved as drugs", this is the most checkable quality disclosure on the site. ⚠ One phrase does not match the rest: the header banner reads "FDA regulated pharmacies", which is loose — 503A pharmacies are licensed and inspected by STATE boards, not regulated by FDA, and Trimi's own body copy says so correctly two screens further down.
Read on August 2026 from https://trytrimi.com
Licensing
Licensed to dispense, and where
Coverage
All 50 states and Washington, D.C.
Read the full licensing claim
Trimi publishes a page for each jurisdiction it serves — 51 in its own sitemap, including one for the District of Columbia — and the index above them states that pricing is "the same $99/mo semaglutide and $125/mo tirzepatide pricing, no matter which state you live in." Coverage is credited to a named clinician network rather than asserted: "licensed providers through Arora Health, a network spanning all 50 states and led by Medical Director Dr. Sean Arora, MD." `statesExcluded` is empty as a matter of evidence — Trimi names no exclusion and publishes a page for every state. Naming the medical director, with a title and a credential, is something only a handful of companies in this roster do. ⚠ No individual prescriber other than the medical director is named, and no licence number is published for the clinician network itself — the licence number Trimi does publish belongs to one of its pharmacies.
Read on August 2026 from https://trytrimi.com
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- It names the trials — "SURMOUNT-1 trial (NEJM)" and "SELECT trial (NEJM)" — so a reader can check the figures rather than take them on trust.
- It states that those figures come from "peer-reviewed clinical trials of the ACTIVE INGREDIENTS", not of its own compounded product — the exact distinction two companies in this wave hold open FDA letters for blurring.
- It states its regulatory category explicitly and correctly: "state-licensed 503A pharmacies", and that its products "are not themselves FDA-approved as drugs".
Show 8 more
- It names two pharmacies and publishes a verifiable licence number for one: VialsRx, Texas Board of Pharmacy #35264.
- It is the only company in this roster to acknowledge a certificate of analysis exists at all.
- It names its medical director with a credential — Dr. Sean Arora, MD, of Arora Health.
- Price does not change with dose: "Same price at every dose — your price never changes as your dose is adjusted."
- It discloses that the headline prices are annual-plan rates rather than presenting them as standing monthly figures.
- It publishes a page for every state it serves — 51 including the District of Columbia — rather than claiming nationwide coverage in the abstract.
- A 6-month money-back promise is published with conditions attached rather than as an unqualified guarantee.
- No FDA warning letter — screened against the live index with a positive control that fired.
- The certificate of analysis is "available on request", so no customer can read one before deciding to buy.
- The $99 and $125 headlines are annual-plan rates; month to month the verified figures are $175 and $235 — roughly 77% and 88% higher.
- The header banner claims "FDA regulated pharmacies". 503A pharmacies are licensed and inspected by state boards, not regulated by FDA — and Trimi's own body copy states this correctly elsewhere.
Show 5 more
- The SELECT figure — a 20% reduction in major heart events — comes from a trial in people with established cardiovascular disease, which the page does not mention.
- Which of the two named pharmacies fills a given order is not disclosed.
- No prescriber other than the medical director is named, and no licence number is published for the clinician network.
- It sells no peptide beyond the two GLP-1s — no sermorelin, no NAD+, nothing else a peptide buyer might want.
- "Up to" carries a lot of weight in both headline figures: 16% and 22% are top-of-range trial results, not typical outcomes.
Verdict
The bottom line
Trimi is what this site has spent thirty-five reviews asking companies to be. It names the trials behind its numbers, then says out loud that those trials tested the active ingredients rather than the compounded product it sells. It names its regulatory category, names two pharmacies, publishes a state board licence number you can check without asking it anything, names its medical director, and is the only company in this entire roster to acknowledge that a certificate of analysis exists. Set against a field where the norm is an uncited percentage and an unnamed pharmacy, that is a different standard of behaviour. Three things keep it short of the mark it nearly reaches: the certificate is available on request rather than published, so you still cannot read one before buying; the $99 headline is an annual-plan rate against $175 month to month; and a banner calls its pharmacies "FDA regulated" when its own body copy correctly calls them state-licensed. If you are buying a compounded GLP-1, this is the most checkable operator in the roster.
Opens trytrimi.com. A link is not a recommendation to take anything.
The sentence that makes a citation honest
Plenty of companies quote a weight-loss percentage. Trimi is the only one in this series that does all three of the things which make quoting one legitimate.
It names the trials. Its claims are labelled "SURMOUNT-1 trial (NEJM)" and "SELECT trial (NEJM)" — not "clinical studies show", not "research suggests". Real trials, in a named journal, that a reader can go and find. 1 2 3
It says whose trials they were:
"Figures are from peer-reviewed clinical trials of the active ingredients (semaglutide and tirzepatide), not a guarantee of individual results. Compounded medications are prepared per individual prescription and are not themselves FDA-approved as drugs."
That is the distinction the entire compounded-GLP-1 category is built on blurring, and it is the specific thing two companies in this review wave are under open FDA warning letters for. Trimi states it unprompted, in the same block as the figures it qualifies.
And it qualifies the numbers. "Up to 16% weight loss" and "up to 22%" — top-of-range trial results, correctly labelled as ceilings rather than expectations.
One thing is left implicit and a reader should supply it: the SELECT figure, a roughly 20% reduction in major adverse cardiovascular events, comes from a trial of 17,604 people with established cardiovascular disease. 2 It is a real and important result. It is not a number a general weight-loss customer should expect to apply to themselves, and the page does not say so.
Full analysis — 6 more sectionsA licence number · The three words that matter · What you will actually pay · Who prescribes it · The one loose phrase · What this means if you are buying
A licence number
Under a heading reading "Named, licensed pharmacies":
"Your medication is compounded by state-licensed 503A pharmacies, including VialsRx (Texas Board of Pharmacy #35264) and GreenwichRx, with a certificate of analysis available on request."
Four unusual things in one sentence.
The regulatory category is stated — 503A, meaning patient-specific compounding by a state-licensed pharmacy. Most of this roster never says which category applies; one claims 503B without being on FDA's register.
The pharmacies are named, which perhaps a third of this category manages.
One carries a state board licence number. That is the only verifiable identifier published by any company in this review series — you can check #35264 against the Texas Board of Pharmacy without relying on anything Trimi tells you.
And a certificate of analysis is acknowledged to exist, which nobody else here does at all.
Trimi also states the preparation basis correctly: "Compounded semaglutide and tirzepatide are prepared per individual prescription by a state-licensed pharmacy and are not FDA-approved as drugs."
The three words that matter
"Available on request."
A certificate of analysis available on request is not a published certificate. A prospective customer — someone deciding whether to spend $99 or $175 a month on an injectable — still cannot read one before committing. They can ask afterwards.
This review therefore records that Trimi describes a testing regime and that no certificate is public. Both halves are true, and collapsing them would let an acknowledgement read as a document.
It remains the closest any company in this roster comes. Everyone else publishes nothing and mentions nothing.
What you will actually pay
Trimi's headline is "$99/mo semaglutide and $125/mo tirzepatide, no matter which state you live in", and to its credit it tells you the condition:
"Compounded semaglutide is $99 a month and tirzepatide $125 a month on annual plans."
Month to month, the verified figures are $175 and $235 — about 77% and 88% above the headline.
Two genuinely good things sit alongside that. Dose does not change the price: "Same price at every dose — your price never changes as your dose is adjusted", which for drugs designed to be titrated upward over months is worth real money and removes the commonest hidden escalation in this category. And a 6-month money-back promise is published with its conditions attached rather than as an unqualified guarantee.
Who prescribes it
Named, and with a credential: "licensed providers through Arora Health, a network spanning all 50 states and led by Medical Director Dr. Sean Arora, MD."
Trimi publishes a page for every jurisdiction it serves — 51 in its own sitemap, including the District of Columbia — rather than asserting nationwide coverage and leaving the exceptions undiscovered.
(Arora Health also provides the clinical layer for another company reviewed on this site, and VialsRx appears as a named pharmacy for two others. A shared clinical and pharmacy layer is common in this category and is not grounds to treat the brands as duplicates.)
The one loose phrase
Trimi's header banner reads "FDA regulated pharmacies".
That is not right, and Trimi's own body copy proves it knows better: 503A pharmacies are licensed and inspected by state boards of pharmacy, not regulated by FDA — which is exactly what the "state-licensed 503A pharmacies" sentence two screens down says. The banner is loose in the one direction this category is routinely loose in, on a site that otherwise gets the distinction right.
What this means if you are buying
If you want a compounded GLP-1 from the most checkable operator in this roster, this is it. You can look up the pharmacy's licence number yourself, read the trials it cites, and see in writing that those trials tested the ingredient rather than the product you will receive.
Budget on the real number: $175 a month for semaglutide and $235 for tirzepatide unless you are committing to a year. Dose increases will not change it.
Ask for the certificate of analysis before you pay rather than after — Trimi says one exists, which already puts you ahead of every other company reviewed here, and there is no reason to wait until the vial has arrived to see it.
And for a peptide buyer more broadly: Trimi sells the two GLP-1s and nothing else.
Questions
Frequently asked questions
Does Trimi publish a certificate of analysis?
It says one exists and does not publish it. The exact wording is that its medication is compounded by state-licensed 503A pharmacies "with a certificate of analysis available on request". That is a meaningful distinction in both directions. No other company in this review series mentions a certificate of analysis at all — so acknowledging one is a real first. But a certificate available on request is not a public certificate: someone deciding whether to spend $99 or $175 a month still cannot read one before committing, only afterwards. This review therefore records testing as claimed and no certificate as public. If you buy, ask for it before you pay rather than after.
Are Trimi's weight-loss figures accurate?
Yes, and it is the only company here that lets you check them. It labels its claims "SURMOUNT-1 trial (NEJM)" and "SELECT trial (NEJM)" and reports "up to 16%" and "up to 22%" weight loss plus a "20% lower risk of major heart events" — figures that match those trials, with "up to" correctly marking them as top-of-range rather than typical. It then adds the sentence that makes citing them honest: the figures come from "peer-reviewed clinical trials of the active ingredients (semaglutide and tirzepatide), not a guarantee of individual results", and compounded medications "are not themselves FDA-approved as drugs". One caveat Trimi leaves implicit: SELECT enrolled 17,604 people with established cardiovascular disease, so its 20% risk reduction is not a figure a general weight-loss customer should expect to apply to themselves.
What does Trimi actually cost?
$175 a month for compounded semaglutide and $235 for tirzepatide if you pay month to month. The advertised $99 and $125 are annual-plan rates, and Trimi says so — "Compounded semaglutide is $99 a month and tirzepatide $125 a month on annual plans" — which is more than most of this category discloses. Two things genuinely in your favour: the price does not change as your dose is titrated upward ("Same price at every dose"), which removes the commonest hidden escalation in compounded GLP-1 pricing; and a 6-month money-back promise is published with its conditions attached.
Which pharmacy makes Trimi's medication?
One of two, and Trimi publishes something no other company in this roster does — a licence number. Its site states that medication is compounded by "state-licensed 503A pharmacies, including VialsRx (Texas Board of Pharmacy #35264) and GreenwichRx". You can verify #35264 against the Texas Board of Pharmacy independently, without relying on anything Trimi says. It also names the clinical side: Arora Health, led by Medical Director Dr. Sean Arora, MD. What it does not disclose is which of the two pharmacies fills a given order. One correction worth knowing: a banner on the site calls these "FDA regulated pharmacies", which is loose — 503A pharmacies are licensed and inspected by state boards, not by FDA, as Trimi's own body copy correctly states elsewhere.
Glossary
Key terms
Show definitions
- 503A pharmacy
- A state-licensed pharmacy compounding a preparation for an individual named patient against a prescription, inspected by its state board. Not FDA-regulated, and not the same as a 503B outsourcing facility. Trimi states the category explicitly, which most of this roster never does.
- Certificate of analysis
- A laboratory document reporting what a specific batch actually contained — identity, potency, sterility — tied to a lot number. "Available on request" means it exists but cannot be read before purchase.
- SELECT
- A phase 3 trial of semaglutide in 17,604 people with overweight or obesity AND established cardiovascular disease, reporting roughly a 20% reduction in major adverse cardiac events. The population matters: it is not a general weight-loss cohort.
- "Up to"
- A ceiling, not an average. "Up to 22% weight loss" describes the best-performing dose arm of a trial, not what a typical patient should expect.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Trimi's own pages on the date stamped against it, and the URL it came from is published beside it.
Trials read from the registry
Phase, status and enrolment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 3 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- US National Library of Medicine (2026). SELECT — Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity, phase 3, completed, n=17,604, NCT03574597. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03574597
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.